MilliporeSigma Webinars

91. Assess Pyrogenic Risk With The Monocyte Activation Test 2/5/2021

    Microbial risk in pharmaceutical processing cannot be limited to viable microorganisms. Learn how the MAT can help you to assess the pyrogenic risk resulting from your production process.

92. Unlocking The Potential Of mRNA Vaccines And Therapeutics: A Manufacturing Perspective 1/12/2021

    This webinar highlights the potential of mRNA therapies and focuses on the manufacturing process associated challenges, solutions and perspectives from synthesis to delivery.

93. Re-Imagining Vaccine Manufacturing To Address Global Health Challenges 10/27/2020

    In the last decade, biopharmaceutical industries have mobilized quickly in response to pandemics. Developing vaccines and manufacturing large doses in response to an emergency is often constrained by existing platforms and facility configurations. Learn how vaccine manufacturing can evolve to tackle future global health challenges.

94. Addressing The Challenge Of Scalability In Viral Vectors 10/18/2020

    Early viral vector process development for cell and gene therapies is critical to assure a production strategy that supports commercial needs. In this webinar, you will learn the importance of planning for scalability and manufacturability from the earliest stages of process development and how a scalable templated process can reduce time needed to move from product development to commercialization. 

95. Evaluating Viral Clearance For Continuous Processes 10/18/2020

    Is viral clearance a hurdle to implementing continuous processing? Here we share virus spiking alternatives that may pave the way for evaluating viral clearance by chromatography steps.

96. Navigating The Road To Gene Therapy Commercialization 8/27/2020

    With increases in development and investments in the gene therapy field, companies will increasingly be looking at manufacturing and commercialization of their therapies. Road to commercialization goes through a series of process validation phases. In this webinar, we take a closer look at the road to commercialization and focus on addressing primary questions.

97. Downstream Process Intensification For Virus Purification 8/21/2020

    With the rise of gene therapy as a promising treatment modality, the industry is facing increasing pressure to decrease overall manufacturing costs, shorten product development timelines and increase production. This webinar focuses on intensified downstream process using high-productivity, single-use chromatography membrane adsorbers.

98. How To Ensure Biosafety Of Novel Viral Therapies 11/7/2019

    While no viral contamination has been reported so far for novel viral therapies, it is important to learn from historical experience and leverage improved manufacturing and testing methods to increase their safety. 

99. Process Development for Cell Therapy and Viral Gene Therapy 10/29/2019

    In this webinar, we discuss our strategies for developing lentivirus and adeno associated virus (AAV) and the impact these early decisions can have on commercial readiness.

100. A Single-Use, Integrated mAb Biosimilars Purification Platform 10/10/2019

     In biopharma, there's a shift toward higher productivity processes resulting in improved economics without compromising quality. Integrated continuous production technologies are gaining interest.